ISRCTN98865222 https://doi.org/10.1186/ISRCTN98865222

Trial of topical British Anti-Lewisite (BAL) to prevent cyclophosphamide induced alopeciae

Submission date 01/07/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 01/07/2001	**Overall study status** Completed	
Last Edited 26/02/2015	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
- - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
BAL

Study information

Scientific Title
Trial of topical British Anti-Lewisite (BAL) to prevent cyclophosphamide induced alopeciae

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Lung (non-small cell) cancer

Interventions
1. BAL Group: Chemotherapy, single-agent cyclophosphamide plus topical application of BAL. BAL lotion to be applied to posterior half of the scalp including occipital parietal areas two hours before and within 15 minutes of completing cyclophosphamide infusion. BAL to be left on the scalp for two to three hours.
2. Control Group: Chemotherapy, single-agent cyclophosphamide.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
British Anti-Lewisite, cyclophosphamide

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/2000

Completion date
31/12/2003

Eligibility

Key inclusion criteria
1. Lung cancer patients due to receive single-agent cyclophosphamide
2. Hair to be cut as short as possible before application of BAL

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/2000

Date of final enrolment
31/12/2003

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

Sponsor details
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type
Charity

Website
http://www.cancer.org.uk

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration